1. Scrip
  2. >>R&D

Pharma Companies Get On Board With Regeneron To Speed Biobank Sequencing

 
• By Alexandra Shimmings

AbbVie, Alnylam, AstraZeneca and Pfizer join forces with Regeneron to speed up the sequencing of the 500,000 genetic samples in the UK's Biobank.

Conductor
All aboard the sequencing train • Source: Shutterstock

An initiative to sequence genetic samples from 500,000 participants in the UK's Biobank by Regeneron Pharmaceuticals Inc. has received a boost with new funding from four pharma companies, which should speed the completion of the work by nearly three years.

The "pre-competitive" consortium will see AbbVie Inc., Alnylam Pharmaceuticals Inc., AstraZeneca PLC and Pfizer Inc. each...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.